Skip to main content
OpenTrials
Completed

NCT Number: NCT06630481

Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade

1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response. 2. Among various pathological tumor regression grading systems, the College of American Pathologists (CAP) system is commonly used to predict chemo-responsiveness and survival. 3. This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoadjuvant Therapy Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms Pathological Complete Response

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (aged >18 years) who underwent pancreatic resection after NAT at a single center between January 2009 and December 2023.
  • Patients were initiated on NAT after confirming PDAC diagnosis based on pathological examination.

Exclusion criteria

  • Patients without a reported CAP grade
  • Patients who underwent palliative surgery
  • Patients who received NAT outside the specified protocol due to incomplete information.

Treatment and study plan

neoadjuvant therapy

Drug

Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.

Primary outcomes

  1. 5-year overall survival

    Time frame: assessed up to 60months

    from diagnosis to any cause of death

  2. 5-year disease-free survival

    Time frame: assessed up to 60months

    defined as the duration between the date of surgery and the occurrence of the first instance of recurrence, death, or the last follow-up date.

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Acronym: CAP with NAT

Important dates

Study start
2009
Primary completion
2023
Study completion
2024
First posted
Oct 8, 2024
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.